GSK5764227

DRUG4 trials

Sponsors

GlaxoSmithKline, University Health Network, Toronto

Conditions

Gastrointestinal NeoplasmsNeoplasmsRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Active, not recruitingNCT05277051

GlaxoSmithKlineNeoplasms

Start: 2022-03-22End: 2027-08-31Updated: 2026-05-22

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

RecruitingNCT06885034

GlaxoSmithKlineGastrointestinal Neoplasms

Start: 2025-06-11End: 2028-06-23Target: 320Updated: 2025-11-18

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

RecruitingNCT07277270

GlaxoSmithKlineNeoplasms

Start: 2025-12-03End: 2028-09-29Target: 84Updated: 2026-01-07

Phase 2

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

RecruitingNCT07408063

University Health Network, TorontoRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2026-04-27End: 2031-03-01Target: 30Updated: 2026-04-29

Related Papers

A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.

Journal of Clinical Oncology2026-01-10